Literature DB >> 11031097

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

H Arai1, K Ishiguro, H Ohno, M Moriyama, N Itoh, N Okamura, T Matsui, Y Morikawa, E Horikawa, H Kohno, H Sasaki, K Imahori.   

Abstract

Cerebrospinal fluid (CSF) tau protein phosphorylated at both Thr231 and Ser235 sites (CSF/phospho-tau(231-235)) and total tau (CSF/total-tau) were quantified by sandwich ELISA in 20 patients with mild cognitive impairment (MCI) who eventually developed AD on follow-up as well as seven memory complainers with no objective memory loss. 13/20 (65%) of the MCI patients had high CSF/total-tau and detectable levels of CSF/phospho-tau(231-235), whereas these markers were low and under a detectable level in all of the memory complainers. Although either a total-tau, phospho-tau measurement or a combination of these can help in predicting if MCI will develop AD, our results suggest that the pathogenic steps of AD may be at the stage that finally leads to an accumulation of abnormally phosphorylated tau and neuron death, at least in some brain areas, when MCI patients present with the earliest detectable clinical symptoms of dementia. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11031097     DOI: 10.1006/exnr.2000.7501

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  33 in total

1.  CSF biomarkers for Alzheimer's disease: current utility and potential future use.

Authors:  David M Holtzman
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain.

Authors:  Sara L Montgomery; Michael A Mastrangelo; Diala Habib; Wade C Narrow; Sara A Knowlden; Terry W Wright; William J Bowers
Journal:  Am J Pathol       Date:  2011-08-09       Impact factor: 4.307

3.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.

Authors:  Miroslaw Brys; Elizabeth Pirraglia; Kenneth Rich; Sindre Rolstad; Lisa Mosconi; Remigiusz Switalski; Lidia Glodzik-Sobanska; Susan De Santi; Ray Zinkowski; Pankaj Mehta; Domenico Pratico; Leslie A Saint Louis; Anders Wallin; Kaj Blennow; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-09-24       Impact factor: 4.673

Review 4.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

Review 5.  Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.

Authors:  Anders Lönneborg
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

6.  Commentary on "Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease." Biochemical biomarkers of late-life dementia.

Authors:  Christopher M Clark; Domenico Pratico; Lesley M Shaw; Susan Leight; Sharon X Xie; Amy Gu; Virginia M-Y Lee; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2006-10       Impact factor: 21.566

7.  Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.

Authors:  M J de Leon; L Mosconi; J Li; S De Santi; Y Yao; W H Tsui; E Pirraglia; K Rich; E Javier; M Brys; L Glodzik; R Switalski; L A Saint Louis; D Pratico
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

8.  Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls.

Authors:  Yi-Yu Chou; Natasha Leporé; Christina Avedissian; Sarah K Madsen; Neelroop Parikshak; Xue Hua; Leslie M Shaw; John Q Trojanowski; Michael W Weiner; Arthur W Toga; Paul M Thompson
Journal:  Neuroimage       Date:  2009-02-21       Impact factor: 6.556

9.  Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies.

Authors:  Rachel Mistur; Lisa Mosconi; Susan De Santi; Marla Guzman; Yi Li; Wai Tsui; Mony J de Leon
Journal:  J Clin Neurol       Date:  2009-12-31       Impact factor: 3.077

10.  Genomic and Proteomic Biomarker Discovery in Neurological Disease.

Authors:  Rilee H Robeson; Andrew M Siegel; Travis Dunckley
Journal:  Biomark Insights       Date:  2008-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.